Biden's Covid vaccine patent waiver support prompts pharma backlash
The Biden administration’s “unprecedented” decision to support a temporary waiver of intellectual property rights to help developing nations produce Covid-19 vaccines has quickly been welcomed by a global coalition of campaigners but triggered a fierce backlash from the pharmaceutical industry.
Katherine Tai, the US trade representative, overrode objections from drugs executives to back a proposal through the World Trade Organisation designed to help end the pandemic.
“This is a global health crisis and the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures,” she announced on Wednesday, as part of two-day WTO meeting.
The US move was welcomed as a “monumental moment in the fight” and a “powerful example of American leadership to address global health challenges” by Tedros Adhanom Ghebreyesus, head of the
More on: www.thetimes.co.uk